Cancer

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J decides against Erleada+Zytiga combination prostate canc...

Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it didn’t improve survival compared with

Events

Partner Content

Non-Small Cell Lung Cancer Drug Development Summit

Largest solid tumor indication: The definitive forum

News

Activist investor Elliott builds stake in GSK after fresh tr...

Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to t

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.

News